Introduction
5-Fluorouracil (5-FU) is one of the most widely used anticancer agents and has been the mainstay of chemotherapy for many gastrointestinal malignancies, including colorectal cancer (CRC). 5-FU is converted into fl uorodeoxyuridine monophosphate (FdUMP) and this molecule inhibits the activity of a key enzyme, thymidylate synthase (TS), required for DNA synthesis. Inhibition of TS by FdUMP is achieved through the formation of a ternary complex with the reduced folate 5-10-methylene tetrahydrofolate (CH 2 FH 4 ) . Experimental work has demonstrated that elevated cellular concentrations of CH 2 FH 4 lead to stabilization of the ternary complex and stronger inhibition of TS. 1, 2 Consistent with this, the addition of folinic acid (leucovorin) to 5-FU improves the response rates and survival of CRC patients.
3,4 A 6-month course of 5-FU/leucovorin is now standard chemotherapy for most stage III and many stage II colon cancer patients.
The aim of personalized medicine is to deliver the most effective drugs to individual patients while simultaneously minimizing the adverse side effects of treatment. This goal is especially important for the new generation of targeted but expensive treatments such as cetuximab and bevacizumab. While 5-FU-based therapies are considerably less expensive, it would still be very helpful to identify colon cancer patients who are likely to respond. This is especially important for stage II cases where a survival benefi t from 5-FU adjuvant chemotherapy has yet to be fi rmly established. 5 Despite considerable advances in our understanding of the mechanism of 5-FU action, the identifi cation of clinically useful molecular markers for predicting the response to 5-FU remains elusive. In this review, we summarize the evidence suggesting that colon cancers with the CpG island methylator phenotype (CIMP) represent the 5-FUresponsive subgroup.
Received: October 21, 2008 Abstract The CpG island methylator phenotype (CIMP+) of colorectal cancer (CRC) occurs predominantly in the proximal colon and is characterized by frequent hypermethylation of gene promoter regions. In this review, we present evidence suggesting CIMP+ represents the subgroup of colon cancers that are responsive to 5-fl uorouracil (5-FU)-based treatments. CIMP+ has been associated with survival benefi t from 5-FU in a clinical study of CRC, with additional evidence coming from studies on gastric cancer and tumor cell lines. Elevated concentrations of 5-10-methylene tetrahydrofolate (CH 2 FH 4 ) occur in CIMP+ tumors and are probably due to low expression levels for γ-glutamyl hydrolase (GGH). Clinical and in vitro work has previously shown that high CH 2 FH 4 and low GGH expression levels correlate with good response to 5-FU. Methylation-induced silencing of dihydropyrimidine dehydrogenase, the rate-limiting enzyme in 5-FU degradation, may also provide a link between CIMP+ and good response to 5-FU. The CIMP+-related phenotype referred to as microsatellite instability (MSI+) has been widely investigated as a predictive marker of response to 5-FU, with contradictory results. The interpretation of these studies is likely to be confounded by the fact that some MSI+ tumors occur in the background of CIMP+, but a signifi cant proportion of others do not. Further studies on tumors from randomized clinical trials are required to confi rm the value of CIMP+ and associated molecular features for the prediction of clinical outcome to 5-FU-based chemotherapy.
The CpG island methylator phenotype
The notion of a methylator phenotype for CRC was fi rst proposed in 1999 by Toyota et al. 6 to describe a subset of colorectal tumors with a very high frequency of DNA methylation at "type C" loci. These were defi ned as DNA loci that were methylated in cancer, but not in corresponding normal tissues. Subsequent studies found the CIMP+ trait to be associated with location in the proximal colon, female sex, older age, high tumor grade, mucinous histology, wildtype TP53, microsatellite instability, and BRAF oncogene mutation. [7] [8] [9] [10] [11] Several marker panels have been proposed to standardize the classifi cation of CIMP+, with the most widely adopted defi nition consisting of methylation in three or more of the fi ve loci CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1. 10 The CIMP+ subgroup accounts for 15%-30% of CRC in most large studies of unselected CRC cohorts. [7] [8] [9] [10] [11] For many genes, including putative tumor suppressors such as RUNX3, MLH1, TIMP3, and P16, hypermethylation of CpG islands within the promoter region has been associated with silencing of expression. This is believed to represent an alternative mechanism to mutation and loss of heterozygosity (LOH) for the inactivation of tumor suppressor genes. Indeed, CIMP+ CRC is thought to develop from a different premalignant precursor to CIMP− tumors, referred to as the serrated adenoma or hyperplastic polyp. 12 Older, female individuals are at greatest risk of developing CIMP+ tumors. [7] [8] [9] It is interesting to note that older female patients also suffer the most toxicity to 5-FU chemotherapy, 13, 14 raising the possibility that a common mechanism is responsible for the risks of developing CIMP+ tumors and of toxicity to 5-FU/leucovorin. Although good experimental evidence is still lacking, this could involve increased levels of tissue folate in the colonic mucosa of older females, particularly in the proximal colon. Elevated concentrations of CH 2 FH 4 and FH 4 have been observed in tumors from the proximal colon and in tumors from older patients. 15 Moreover, gene hypermethylation was found to be more frequent in the normal colonic mucosa of female and older CRC patients compared to male and younger patients, respectively. 16 The same sex and age correlations are seen for expression of the DNA methyltransferase, DNMT3b, which was reported to be higher in the liver tissue of females and older individuals. 17 Further investigation of tissue folate and DNA methylation levels in the normal colonic mucosa in relation to age, sex, anatomical site, dietary folate intake, and genetic factors such as the MTHFR C677T polymorphism are important for two reasons. Firstly, such studies may lead to the identifi cation of individuals who are at increased risk of developing CIMP+ colon cancers, thus allowing regular surveillance and perhaps also dietary modifi cation to reduce the risk. Secondly, tissue folate and DNA methylation levels in normal colonic mucosa could have predictive value for toxicity to 5-FU/leucovorin. The wellestablished associations of sex and age with toxicity to 5-FU 13, 14 could, in fact, be surrogate indicators for underlying biological factors such as tissue folate or DNA methylation levels. While both issues clearly merit further research attention, the present review will focus only on the predictive values of the CIMP+ and associated microsatellite instability (MSI+) markers for response to 5-FU-based therapy.
CIMP+ and cellular folate levels
Several indirect lines of evidence suggest that CIMP+ tumors comprise the 5-FU-responsive subgroup of colon cancers. These relate mainly to the link between CIMP+ and intracellular folate metabolism ( Fig. 1) 20 to our knowledge there are no comparable clinical studies published to date for CRC. This is likely to refl ect the diffi culties associated with collection of frozen human tissues and the subsequent biochemical analysis of CH 2 FH 4 levels. Nevertheless, it is surprising these studies have not been carried out in view of the extensive in vitro and animal work showing the importance of intracellular folate levels for therapeutic effi cacy of 5-FU. 18, 19 Expression levels for two of the key enzymes involved in regulating the intracellular folate concentrations have also shown predictive signifi cance for response to 5-FU. Folylpolyglutamate synthase (FPGS) converts intracellular folate to polyglutamated forms that are retained for longer in the cell, thus leading to increased levels. In contrast, γ-glutamyl hydrolase (GGH) removes glutamates thereby lowering the cellular folate level. Lower FPGS activity in the liver metastases of CRC correlates with 5-FU resistance, 21 as would be expected if this led to decreased tumor folate levels. Results from several in vitro studies on tumor cell lines support this clinical fi nding. [22] [23] [24] [25] On the other hand, decreased GGH expression in colon cancer cell lines induced by siRNA resulted in increased sensitivity to 5-FU, presumably due to the better retention of folate. 25 Low GGH expression was also reported recently to correlate with good response to 5-FU-based therapy in a study of metastatic CRC. 26 CIMP+ tumors express signifi cantly lower levels of GGH compared to CIMP− tumors, 27, 28 thus providing an explanation for the higher folate levels observed in these tumors 15 and providing more indirect support for the prediction of better response to 5-FU. FPGS levels were not signifi cantly different, however, between CIMP+ and CIMP− tumors, 27 suggesting this enzyme may play a less important role than GGH in determining cellular folate concentrations in primary CRC.
Microarray analysis has revealed a number of other genes that are differentially expressed between CIMP+ and CIMP− tumors. 28 Gene ontology categories annotated to the differentially expressed genes include several pathways involved in nucleotide metabolism, as well as folate and glutamine metabolism. The results also suggest that metabolic activity responsible for converting 5-FU into the active metabolite FdUMP may be quite different between CIMP+ and CIMP− tumors, resulting in different chemosensitivity. In addition to the inhibition of TS activity, 5-FU could also exert cytotoxic activity through the mis-incorporation of fl uorouridine triphosphate (FUTP) and fl uorodeoxyuridine triphosphate (FdUTP) into RNA and DNA, respectively (Fig. 1) . 29 Further investigation of this mis-incorporation may provide novel insights into differences in chemosensitivity between CIMP+ and CIMP− tumors.
CIMP+ and gene hypermethylation
Remarkably, only one study has so far examined the predictive value of CIMP+ for response to 5-FU in CRC. 30 This work involved 103 stage III CRC patients treated by surgery alone and another 103 patients who were matched for age, sex, and tumor site and who also received adjuvant treatment with 5-FU/leucovorin. CIMP+ patients showed a signifi cant survival benefi t from 5-FU, but not those with CIMP− tumors. Further studies are anticipated using a standard panel of markers to defi ne CIMP+ 10 and involving the analysis of tissues from randomized clinical trials. In support of the observations made in CRC, methylation of p16 was reported to be predictive of survival benefi t from 5-FU in gastric cancer. 31 Moreover, a recent in vitro study showed that cancer cell lines with methylated TIMP3 were more sensitive to 5-FU. 32 Aside from having high intracellular folate concentrations, another possible explanation for CIMP+ tumors showing better response to 5-FU is because of the silencing of critical genes. One candidate for this is the methylationinduced silencing of the dihydropyrimidine dehydrogenase gene (DPYD). DPD enzyme catalyses the rate-limiting step in 5-FU degradation (Fig. 1) and its activity is a major determinant of clinical resistance and toxicity to this agent. 33 Methylation-induced silencing of DPYD has been implicated in the sensitivity of various tumor cell lines to 5-FU. [34] [35] [36] Downregulation of DPD activity in association with DPYD methylation has also been reported in clinical samples; however, this has yet to be correlated with tumor response to 5-FU. 37 Several studies have investigated the prognostic signifi cance of CIMP+ or gene methylation in CRC patients treated with 5-FU. Methylation of MGMT was associated with low risk of recurrence in CRC patients treated with 5-FU-based chemotherapy. 38 In contrast, two studies in advanced CRC reported that methylation of several genes was associated with worse survival in patients who received chemotherapy. 39, 40 A follow-up study by one of these groups found that CIMP+ colon cancer patients had good survival relative to CIMP− patients once adjustment was made for the presence of BRAF mutations. 41 It must be emphasized, however, that such studies do not provide information on whether CIMP+ has predictive value for the response to 5-FU. This requires comparison of clinical response rates or patient survival between CIMP+ patient groups treated with or without chemotherapy.
Microsatellite instability (MSI+) as a surrogate marker for CIMP+
Compared to CIMP+, considerably more work has been carried out on the MSI+ phenotype as a potential molecular predictive marker for response to 5-FU in CRC. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] MSI+ is characterized by frequent alterations in the size of nucleotide repeats due to a defective DNA mismatch repair system. The majority of sporadic MSI+ tumors arise because of methylation-induced silencing of the MLH1 mismatch repair gene 52 and hence MSI+ could be used as a surrogate marker for CIMP+, but with important qualifi cations, as outlined below. Depending on the criteria used to defi ne CIMP+, it has been estimated that 55%-80% of MSI+ tumors in nonselected CRC series are also CIMP+. 7, 8, 11 The remaining MSI+ tumors presumably arise because of MLH1 methylation in the absence of widespread methylation of other genes, or because of somatic or germline mutations that occur in MLH1, MSH2, or other mismatch repair genes.
The underlying cause of MSI+ is likely to be a critical issue in determining the biological and clinical properties of MSI+ tumors, including the response to 5-FU. 53, 54 For example, MSI+ tumors with MLH1 methylation are far more frequent in older, female patients and have a high incidence of BRAF mutation compared to MSI+ tumors without MLH1 methylation. 55, 56 Another illustration is that MSI+ tumors that arise in the proximal colon have different gene expression profi les compared to those arising in the distal colon. 57 Such fundamental differences would be expected to infl uence the response of MSI+ tumors to 5-FU and may explain the discordant results published to date for the predictive value of this marker. None of the studies so far has considered the potential impact of factors such as patient age, tumor site, or MLH1 methylation status on the prognostic or predictive values of MSI+.
Several of the early studies on MSI+ showed associations with either excellent survival, or a survival benefi t, for patients treated with 5-FU. [42] [43] [44] [45] [46] [47] In contrast, other groups have reported a lack of survival benefi t from 5-FU for patients with MSI+ tumors, [48] [49] [50] [51] leading some authors to go as far as proposing that MSI+ patients should not be treated with chemotherapy. 58, 59 There is evidence to suggest that MSI+ patients belonging to the hereditary bowel cancer condition known as Lynch syndrome do not benefi t from 5-FU-based chemotherapy. 60 However, until large-scale clinical studies are carried out on sporadic MSI+ tumors that specifi cally examine the effect of the underlying phenotype (e.g., methylated or nonmethylated MLH1, mutant or wildtype BRAF) on the predictive value of this marker, it would seem prudent to treat all eligible patients with adjuvant 5-FU chemotherapy regardless of their MSI status. This is particularly important in light of a recent metaanalysis showing that MSI+ patients actually gain more benefi t from adjuvant chemotherapy than MSI− patients. 61 Conclusions and future perspectives CIMP+ tumors are a phenotypically distinct subgroup of CRC that comprise approximately one-third of all proximal colon cancers. They are most prevalent in older, female patients and have elevated levels of cellular folate and gene promoter methylation, but lower expression of GGH. Although there is still a paucity of information on the predictive value of CIMP+, the direct and indirect evidence published to date suggests this phenotype may be the 5-FUresponsive subgroup of CRC. Clinical trials of early-stage colon cancer that stratify patients according to CIMP status prior to randomization to 5-FU-based treatments will be required to defi nitively address the question of whether CIMP+ has predictive value. More work is required to identify dietary and genetic risk factors for the development of CIMP+ and whether patients with these tumors are more likely to suffer toxicity from 5-FU-based treatments. Possible associations between CIMP+ and other factors that are likely to infl uence the response to 5-FU chemotherapy also require further investigation, including intracellular folate levels and the expression of TS and DPD. Finally, CIMP+ tumors show high densities of infi ltrating lymphocytes independently of the MSI+ phenotype. 62 This observation suggests that study of the antitumor immune response in CIMP+ patients before and after 5-FU-based chemotherapy may also prove interesting.
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